CYP3A5 and posterior cortical atrophy: CYP3A5 inhibitors can enhance androgen depletion therapy (ADT), while inducers may reduce efficacy [61]; and its polymorphism may specifically decrease the risk of developing low-grade or early stage PCa in the Japanese population [62].